Adlai Nortye Group Ltd ADR ANL

$10.52 -0.33 (-3.04%)

Valuation

Market cap
698,718,000
Revenue TTM
$5,000,000
Net income TTM
$-35,530,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-710.60%
Debt to equity
0.12

Trading

Volume
130,600
Avg volume
258,768
Day's range
$10.22 – $10.79
Shares out
64,398,000
Stochastic %K
64%
Beta
1.36
Analysts
Strong Buy
Price target
$25.60

Price

Company profile

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibi...

Show more

Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies. Its RAS-targeting programs include AN9025, an oral pan-RAS(ON) inhibitor for RAS-driven cancers, and AN4035, a CEACAM5-targeting antibody-drug conjugate that delivers a pan-RAS(ON) inhibitor to tumors. Its immunotherapy programs include AN8025, a tri-functional fusion protein (aPD-L1 x CD86 variant x LAG3 variant) that modulates T-cells and antigen-presenting cells; AN0025, a small molecule EP4 antagonist; and AN4005, an oral small-molecule PD-L1 inhibitor. The company supports its pipeline through an immuno-oncology research and development platform with operations in the United States and China. Adlai Nortye Group Ltd. was formerly known as Adlai Nortye Ltd. and changed its name to Adlai Nortye Group Ltd. in July, 2026. Adlai Nortye Group Ltd. was founded in 2004 and is based in Singapore.

Industry
Biotechnology
Sector
Healthcare
Phone
848 230 7430
Website
https://www.adlainortye.com
Address
77 Robinson Road, 2nd floor #20-01, Singapore, Singapore

Latest news

Stocktwits

GTA_Terminal Nov 9, 1:48 PM
Dark pool check on $ANL: what traded off the exchanges in the latest session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Read the full article for the full details: https://globaltradersacademy.com/articles/anl-technical-levels-chart-options-flow-and-dark-pools-diverge-at-10-28?utm_source=stocktwits&utm_medium=social
0 replies
Alt_Fuel Nov 5, 2:01 PM
$VSTM @doepke_michel Imagine if RVMD had been acquired at the beginning of the year. It would have been a steal for Big Pharma. Now, other assets in the (K)RAS space, in particular, are likely to attract the interest of major players. $ERAS $TNGX $VSTM $ANL $INCY https://x.com/doepke_michel/status/2118314893678121302
0 replies
Merlintrader Nov 1, 5:47 PM
$ANL closed the week at $9.55 (-9.7% w/w, -7.1% Friday), below the 50-day SMA ($13.82) and below the 200-day ($11.39). RSI14 31.6. Support $9.36, resistance $16.74 (20-day range, bottom). Broad market sell-off on Friday. New hub updated: https://www.merlintrader.com/adlai-nortye-anl-stock-hub/
0 replies
focafoca99 Oct 28, 10:24 AM
$ANL scheduled an oral presentation on its AN4035 program at the 38th EORTC-NCI-AACR Symposium.
0 replies
Merlintrader Oct 27, 9:30 PM
$ANL — AN4035 oral presentation at EORTC-NCI-AACR Symposium on 19 Nov in Barcelona. Information only — not investment advice. More details in our hub.
0 replies
Alt_Fuel Oct 16, 9:31 AM
$VSTM $ANL $RVMD SINGAPORE and NORTH BRUNSWICK, N.J., Oct. 15, 2026 - Adlai Nortye Group Ltd. (NASDAQ: ANL)... today announced clinical trial collaboration and supply agreements (CTCSAs) with Eli Lilly $LLY and and Merck KGaA $MRK for the anti-EGFR antibody cetuximab (marketed as ERBITUX®). These agreements will support Adlai Nortye’s ongoing Phase I trial evaluating AN4035, a pan-RAS(ON) inhibitor-based ADC, both as monotherapy and in combination with cetuximab, in CEACAM5-enriched RAS-addicted solid tumors. Adlai Nortye is the sponsor of the trial. Lilly will supply cetuximab at no cost for the U.S. clinical trial sites. Merck KGaA, Darmstadt, Germany will supply cetuximab at no cost for the Australia and China clinical trial sites. https://ir.adlainortye.com/news-releases/news-release-details/adlai-nortye-enters-clinical-collaboration-lilly-and-merck-kgaa
0 replies
Merlintrader Oct 16, 12:19 AM
Latest company news, October 15, 2026: Adlai Nortye signed clinical supply agreements with Lilly (U.S. sites) and Merck KGaA (Australia and China) for cetuximab, to be combined with its pan-RAS ADC AN4035. First AN4035 data are guided for the second half of 2027. Adlai Nortye $ANL Stock Hub: RAS Trials And Cash https://www.merlintrader.com/adlai-nortye-anl-stock-hub/
0 replies
OpenOutcrier Oct 15, 12:26 PM
$ANL (+3.4% pre) Adlai Nortye Strikes Global Clinical Collaboration with $LLY Lilly and $MRK Merck for AN4035 Combination Trial https://ooc.bz/l/117369
0 replies